[
  {
    "6-MP": "6–Mercaptopurin"
  },
  {
    "ALAT": "Alanine-Aminotransferase"
  },
  {
    "ALL": "Acute Lymphoblastic Leukemia"
  },
  {
    "ANSM": "“Agence Nationale de sécurité du médicament et des produits de santé”"
  },
  {
    "ASAT": "Aspartate Amino Transferase"
  },
  {
    "AT": "Anti Thrombin"
  },
  {
    "ATG": "Anti ThymoGlobulin"
  },
  {
    "BID": "Twice a day"
  },
  {
    "BM": "Bone Marrow"
  },
  {
    "BMI": "Body Mass Index"
  },
  {
    "CIR": "Cumulative Incidence of Relapse"
  },
  {
    "CIV": "ContinuousIntravenous"
  },
  {
    "CML": "ChronicMyelogenous Leukemia"
  },
  {
    "CNS": "Central Nervous System"
  },
  {
    "CPM": "Cyclophosphamide"
  },
  {
    "CPP": "“Comité de Protection des Personnes”"
  },
  {
    "CR": "Complete Remission"
  },
  {
    "CRA": "Clinical Research Assistant"
  },
  {
    "CRF": "Case Report Form"
  },
  {
    "CSF": "Cerebro Spinal Fluid"
  },
  {
    "DFS": "Disease free survival"
  },
  {
    "DIVC": "Disseminated Intravascular Coagulation"
  },
  {
    "DMA": "Drug Marketing Authorization"
  },
  {
    "DNR": "Daunorubicin"
  },
  {
    "DVI": "Dexamethasone, Vincristine, ITK"
  },
  {
    "ECG": "Electrocardiogram"
  },
  {
    "ECOG": "Eastern Cooperative Oncology Group (= PS)"
  },
  {
    "FFD": "Form of Functions Delegation"
  },
  {
    "FFP": "Fresh Frozen Plasma"
  },
  {
    "FGM": "France Greffe de Moelle"
  },
  {
    "FR": "Shortening Fraction"
  },
  {
    "GCP": "Good Clinical Practice"
  },
  {
    "G-CSF": "Granulocyte colony-stimulating factor"
  },
  {
    "GNB": "Gram Negative Bacteria"
  },
  {
    "GPB": "Gram Positive Bacteria"
  },
  {
    "GVH": "Graft versus Host"
  },
  {
    "HCR": "Hematologic Complete Remission"
  },
  {
    "HD": "High Dose"
  },
  {
    "HLA": "Human Leukocyte Antigen"
  },
  {
    "HR": "High Risk"
  },
  {
    "HSC": "Hematopoietic Stem Cells"
  },
  {
    "HSCT": "Haematopoietic Stem Cell Transplantation"
  },
  {
    "ISC": "Independent Surveillance Committee"
  },
  {
    "IT": "Intra-thecal"
  },
  {
    "IUD": "Intrauterine Device"
  },
  {
    "IV": "Intravenous"
  },
  {
    "IVD": "Intravenous Direct"
  },
  {
    "LR": "Low Risk"
  },
  {
    "LWH": "Low Weight Heparin"
  },
  {
    "MAC": "Myelo Ablative Conditioning"
  },
  {
    "MMolR": "Major Molecular Response"
  },
  {
    "MRD": "Minimal Residual Disease"
  },
  {
    "MRI": "Magnetic Resonance Imaging"
  },
  {
    "MTX": "Methotrexate"
  },
  {
    "NRM": "Non Relapse related Mortality"
  },
  {
    "NYHA": "“New York Heart Association”"
  },
  {
    "OS": "Overall survival"
  },
  {
    "ANC": "Polymorphonuclears"
  },
  {
    "PO": "Per Os"
  },
  {
    "PS": "Performans Status (= ECOG)"
  },
  {
    "RBC": "Red Blood Cells"
  },
  {
    "RFS": "Relapse-Free Survival"
  },
  {
    "RTC": "Reduced Toxicity Conditioning"
  },
  {
    "SAE": "Serious Adverse Event"
  },
  {
    "SC": "SubCutaneous"
  },
  {
    "SGOT": "Serum Glutamic OxaloaceticTransferase"
  },
  {
    "SGPT": "Serum GlutamopyruvateTransferase"
  },
  {
    "SIV": "Slow Intravenous"
  },
  {
    "SPC": "Summary of Product Characteristics"
  },
  {
    "SR": "Standard Risk"
  },
  {
    "TBI": "Total Body Irradiation"
  },
  {
    "TD": "Total Dose"
  },
  {
    "TDM": "Tomodensitometry"
  },
  {
    "TKI": "Tyrosine Kinase Inhibitor"
  },
  {
    "TLP": "Traumatic Lumbar Puncture"
  },
  {
    "TUA": "Temporary Usage Authorization"
  },
  {
    "ULN": "Upper Limit of Normal"
  },
  {
    "VCR": "Vincristine"
  },
  {
    "VDS": "Vindesine"
  },
  {
    "VEF": "Ventricular Ejection Fraction"
  },
  {
    "VHR": "Very High Risk"
  },
  {
    "VP-16": "Etoposide"
  },
  {
    "WBC": "White Blood Cells"
  }
]